TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3890228

Group type: EXPERIMENTAL
Intervention: Gentamicin (280 mg, single dose, intramuscularly)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Kanamycin (2 g, single dose, intramuscularly)
Number of subjects: 415
Study: 31380887

Group type: EXPERIMENTAL
Intervention: Healthcare system factors (identified through thematic analysis)
Number of subjects: 19
Study: 30447669

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 292

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 292
Study: 26978136

Group type: EXPERIMENTAL
Intervention: Subfascial administration of 3 g of tranexamic acid (TXA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group without TXA
Number of subjects: 200
Study: 24650447

Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Formoterol (12 µg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Doxofylline (400 mg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Montelukast (10 mg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Tiotropium (18 µg)
Number of subjects: 167
Study: 22810981

Group type: EXPERIMENTAL
Intervention: Folate supplementation (1 mg/d)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 20571496

Group type: EXPERIMENTAL
Intervention: Vitamin B(6) supplementation (100 mg/day) plus 5 mg/day folic acid
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (5 mg/day folic acid only)
Number of subjects: 35
Study: 18055960

Group type: EXPERIMENTAL
Intervention: Postcard intervention (plus treatment as usual)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study: 16032446

Group type: EXPERIMENTAL
Intervention: High-dose buprenorphine (BH group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine (BL group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 11878654

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Paracetamol + NSAID
Number of subjects: 41

Group type: COMPARATOR
Intervention: NSAIDs alone
Number of subjects: 41
Study: 10438047

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: HbOC vaccine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: HbNOMP vaccine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: All three vaccines
Number of subjects: 135
Study: 7605834

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2341658

Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b gel (30 million IU/gm), applied 4 times a day for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo preparation, applied 4 times a day for 4 weeks
Number of subjects: 24
Study: 6989438

Group type: EXPERIMENTAL
Intervention: Vitamin D supplements (ergocalciferol, 1000 IU/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 31744313

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Local Corticosteroid Injection (LCI)
Number of subjects: 96
Study: 30655275

Group type: EXPERIMENTAL
Intervention: Voxelotor 500-1000 mg per day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Voxelotor 700 or 900 mg per day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Voxelotor 900 mg per day for 6 months (extension study)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 28581919

Group type: EXPERIMENTAL
Intervention: Bulk fill resin composite (Tetric EvoCeram Bulk Fill [TB])
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nanofill resin composite (Filtek Ultimate [FU])
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (TB and FU)
Number of subjects: 50
Study: 26440636

Group type: EXPERIMENTAL
Intervention: Postprandial exercise (E trial)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (C trial)
Number of subjects: 15
Study: 23356886

Group type: EXPERIMENTAL
Intervention: 14-day regimen with high-dose PPI (lansoprazole 60 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 1 g once daily)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 7-day regimen with high-dose PPI (lansoprazole 60 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 1 g once daily)
Number of subjects: 110
Study: 20966907

Group type: EXPERIMENTAL
Intervention: Parent-only (PO) treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Parent + child (PC) treatment
Number of subjects: 80
Study: 19943573

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 30
Study: 17354538

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 14734329

Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 11517419

Group type: EXPERIMENTAL
Intervention: Therapeutics for progressive multifocal leukoencephalopathy (PML)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim analyses, toxicity management, validation of secondary clinical measures
Number of subjects: 0
Study: 9681723

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 14
Study: 8156447

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with Dermatophagoides pteronyssinus at high doses
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3264709

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1 for induction and maintenance with 70% nitrous oxide in oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiamylal 4.0 mg kg‐1 for induction and maintenance with 70% nitrous oxide in oxygen
Number of subjects: 0
Study: 31321928

Group type: EXPERIMENTAL
Intervention: Morning dose first (AB sequence)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Evening dose first (BA sequence)
Number of subjects: 60
Study: 27476354

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Ibuprofen (Control)
Number of subjects: 1000
Study: 26161657

Group type: EXPERIMENTAL
Intervention: Pro-Breastfeeding and Healthy Complementary Feeding Intervention
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 323
Study: 24391767

Group type: EXPERIMENTAL
Intervention: 1-T horizontal open MR scanner
Number of subjects: 93

Group type: COMPARATOR
Intervention: 1.5-T short-bore MR scanner
Number of subjects: 93
Study: 20721883

Group type: EXPERIMENTAL
Intervention: Taribavirin (TBV) 20 mg/kg/day
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Taribavirin (TBV) 25 mg/kg/day
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Taribavirin (TBV) 30 mg/kg/day
Number of subjects: 278

Group type: COMPARATOR
Intervention: Ribavirin (RBV) 800-1400 mg/day
Number of subjects: 278
Study: 18279048

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 2
Study: 15841403

Group type: EXPERIMENTAL
Intervention: Plastic curettes and rinsing with chlorhexidine digluconate (P)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrasonic system (U)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (Y)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unworn titanium discs (C)
Number of subjects: 80
Study: 12578927

Group type: EXPERIMENTAL
Intervention: Palmar NC test with cut-off value of 0.5 msec; sensitivity 64.0%
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: D4 NC test with cut-off value of 0.7 msec; sensitivity 71.2%
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: D2 NC test with cut-off value of 44 m/sec; sensitivity 44.8%
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Palmar NC test with cut-off value of 0.4 msec; sensitivity for pretest probabilities >or=75%
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: D4 NC test with cut-off value of 0.5 msec; sensitivity for pretest probabilities >or=75%
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: D2 NC test with cut-off value of 48 m/sec; sensitivity for pretest probabilities >or=75%
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Normal test values; pretest probabilities <25%
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Rigid cut-off values; sensitivity <95%
Number of subjects: 225
Study: 10540659

Group type: EXPERIMENTAL
Intervention: Cragg thrombolytic brush catheter
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pulsed spray
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 77
Study: 9005788

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once a day for 7 to 14 days (average 11 days), administered intravenously for the first 3-5 days and then orally
Number of subjects: 15
Study: 2007937

Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant treatment
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Rescue surfactant treatment
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Surfactant treatment (both prophylactic and rescue)
Number of subjects: 246
Study: 369009

Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation (0.1% available iodine)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Saline solution irrigation (Control)
Number of subjects: 168
Study: 30786157

Group type: EXPERIMENTAL
Intervention: Melatonin 0.075 mg/kg (maximum 5 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Melatonin 0.15 mg/kg (maximum 10 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg/kg (maximum 20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Melatonin (all dose levels)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Concomitant chemotherapy
Number of subjects: 9
Study: 28575414

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AMB) at 5 mg/kg intravenously, twice weekly
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 25740641

Group type: EXPERIMENTAL
Intervention: Wireless hands-free surgical pointer (WHaSP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional methods (without WHaSP)
Number of subjects: 103
Study: 23636036

Group type: EXPERIMENTAL
Intervention: Perennial immunotherapy (PIT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Preseasonal immunotherapy (PSIT)
Number of subjects: 120
Study: 19684411

Group type: EXPERIMENTAL
Intervention: D‐KW/R‐BW ratio <or=4.25
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: D‐FRV/R‐BW ratio <or=5.14
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: D‐SKGFR/R‐BW ratio <or=1.06
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: D‐FRV
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 44
Study: 17335562

Group type: EXPERIMENTAL
Intervention: Clinical model including standard clinical signs and symptoms (fever, cough, sputum production, abnormal chest auscultation, dyspnea)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Clinical model including PCT and hsCRP
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Highly sensitive C-reactive protein (hsCRP)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Total leukocyte count
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) for predicting bacteremia
Number of subjects: 545
Study: 15082209

Group type: EXPERIMENTAL
Intervention: 2-stage implant
Number of subjects: 42

Group type: COMPARATOR
Intervention: 1-stage implant
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 42
Study: 11174430

Group type: EXPERIMENTAL
Intervention: Intermittent harmonic imaging (IHI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intermittent fundamental imaging
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Videodensitometry
Number of subjects: 12
Study: 9924848

Group type: EXPERIMENTAL
Intervention: Nitroglycerin/N-acetylcysteine (NTG/NAC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Furosemide/morphine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study: 7999403

Group type: EXPERIMENTAL
Intervention: Anti-emetic treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurses' assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients' assessment
Number of subjects: 0
Study: 3186615

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg sustained release tablets once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Verapamil 120 mg conventional tablets administered twice daily
Number of subjects: 12
Study: 29562260

Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger followed by specialized regimen (1500 IU hCG) at time of oocyte retrieval plus oral estradiol and intramuscular progesterone during luteal phase
Number of subjects: 190

Group type: COMPARATOR
Intervention: hCG trigger (5000 IU) with luteal support (oral estradiol and vaginal progesterone)
Number of subjects: 190
Study: 28252533

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy (arm A)
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy plus cetuximab (arm B)
Number of subjects: 1603

Group type: COMPARATOR
Intervention: dNLR < 2.2
Number of subjects: 1603
Study: 25466953

Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/d) for 20 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 64
Study: 22586252

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aerobic exercise (AE)
Number of subjects: 56
Study: 21467190

Group type: EXPERIMENTAL
Intervention: Tramadol (50, 100, 200, and 400 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydromorphone (4 and 8 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methylphenidate (30 and 60 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18308793

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 46
Study: 17544335

Group type: EXPERIMENTAL
Intervention: Banded gastric bypass (n = 46)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonbanded gastric bypass (n = 44)
Number of subjects: 90
Study: 15153211

Group type: EXPERIMENTAL
Intervention: Clonidine (2 microg.kg(‐1)) added to bupivacaine (1 mg.kg(‐1) 0.125%)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline added to bupivacaine (1 mg.kg(‐1) 0.125%)
Number of subjects: 36
Study: 11444468

Group type: EXPERIMENTAL
Intervention: Combination of colloidal bismuth subcitrate and metronidazole or omeprazole, clarithromycin and amoxycillin for H. pylori eradication
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate for anaemia treatment
Number of subjects: 8
Study: 9765010

Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg/day for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nystatin (1 mL 4 times a day for 21 days)
Number of subjects: 60
Study: 7824094

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment as mono-therapy (n = 36) or polytherapy (n = 16) with a mean dosage of 17 mg/kg body weight.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment in polytherapy (n = 16).
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment as a nonretarded formulation.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment.
Number of subjects: 52
Study: 3385554

Group type: EXPERIMENTAL
Intervention: Glycine-fortified ORS (55 or 110 mmol/L glycine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard WHO/ORS
Number of subjects: 0
Study: 31343447

Group type: EXPERIMENTAL
Intervention: New HA fillers with decreased BDDE crosslinking
Number of subjects: 90

Group type: COMPARATOR
Intervention: Commercially available comparator gels
Number of subjects: 90
Study: 28859245

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS; Tisseel)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Biodegradable synthetic polyurethane foam (Nasopore®)
Number of subjects: 35
Study: 27992027

Group type: EXPERIMENTAL
Intervention: Music listening for 15 minutes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional pediatric surgical care
Number of subjects: 52
Study: 24983279

Group type: EXPERIMENTAL
Intervention: Early surgical decompression (<24 hours)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Late surgical decompression (24‐72 hours)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Early surgical decompression
Number of subjects: 35

Group type: COMPARATOR
Intervention: Late surgical decompression
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both early and late surgical decompression
Number of subjects: 35
Study: 23088416

Group type: EXPERIMENTAL
Intervention: Biceps tenotomy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Biceps tenodesis
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Biceps tenotomy and tenodesis
Number of subjects: 128
Study: 19757207

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration (FNA)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Fine Needle Capillary (FNC)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Both techniques (FNA and FNC)
Number of subjects: 260
Study: 17320585

Group type: EXPERIMENTAL
Intervention: Awake video‐assisted thoracoscopic bullectomy with pleural abrasion under sole thoracic epidural anesthesia
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Awake video‐assisted thoracoscopic bullectomy with pleural abrasion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (general anesthesia with single‐lung ventilation)
Number of subjects: 43
Study: 15874923

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg twice daily, supplemented by intravenous doses when necessary)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 103
Study: 11983815

Group type: EXPERIMENTAL
Intervention: palm oil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: transesterified palm oil
Number of subjects: 10
Study: 9718869

Group type: EXPERIMENTAL
Intervention: Splenic irradiation
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Age over 40 years
Number of subjects: 1391

Group type: COMPARATOR
Intervention: No splenectomy/no splenic irradiation
Number of subjects: 1391
Study: 7991879

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study: 2463980

Group type: EXPERIMENTAL
Intervention: Methotrexate followed by irradiation
Number of subjects: 170

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 170
Study: 31586370

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Number of subjects: 100
Study: 28468739

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance (25 mg po for 21 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 30
Study: 26125454

Group type: EXPERIMENTAL
Intervention: Local incision warming (6 post-operative treatments)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Non-warming
Number of subjects: 146
Study: 24251360

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of acenocoumarol or phenprocoumon
Number of subjects: 548

Group type: COMPARATOR
Intervention: Clinically guided dosing of acenocoumarol or phenprocoumon
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing
Number of subjects: 548

Group type: COMPARATOR
Intervention: Clinically guided dosing
Number of subjects: 548
Study: 21941167

Group type: EXPERIMENTAL
Intervention: EFV/LPV
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: LPV
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EFV
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: LPV/EFV
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Week 1 HIV-RNA change
Number of subjects: 68
Study: 18385963

Group type: EXPERIMENTAL
Intervention: Empiric studies concerning the treatment of depressive disorders in children and adolescents; specific interventions not detailed.
Number of subjects: 0
Study: 17161074

Group type: EXPERIMENTAL
Intervention: Special compression undergarment
Number of subjects: 481

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 481
Study: 14648923

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lepirudin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART-123
Number of subjects: 0
Study: 10739784

Group type: EXPERIMENTAL
Intervention: Patient perceptions of the organization and structure of the peritoneal dialysis facility
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient perceptions of the dialysis regimen
Number of subjects: 30
Study: 8922764

Group type: EXPERIMENTAL
Intervention: Droperidol 0.04 mg.mg-1 of PCA morphine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All treatment groups (including droperidol 0.0 and 0.02 mg.mg-1 of PCA morphine)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PCA droperidol
Number of subjects: 71
Study: 1557573

Group type: EXPERIMENTAL
Intervention: Bayesian methods for monitoring and analysis
Number of subjects: 0